Abstract
p38α MAPK, a key therapeutic target in HNSCC can be considered as a prognostic marker and is implicated in response to radiation-therapy (RT). We compared the outcome of treatment viz. RT (group-I) and concurrent-RT (combination of RT with chemotherapy or surgery, group-II) with respect to p38α MAPK in HNSCC. The case-controlled study was performed on 143 HNSCC patients. From these p38α estimation was done thrice only for 104 patients (52 each in group-I and II), at pre, during and post-therapy periods using surface Plasmon resonance (SPR) technology, ELISA and western blot analysis. In HNSCC the over-expressed p38α levels declined after treatments in both the groups. The patients receiving only RT had a lower p38α level than those treated with concurrent-RT (p=0.009). Hence, p38α was found to be responsive to RT in HNSCC and it may be useful in predicting the treatment outcome and further improve the prognosis of disease in addition to clinical parameters.
Keywords: p38α, HNSCC, radiation therapy, chemotherapy, surgery.
Current Cancer Therapy Reviews
Title:Comparative Analysis of Current Modality of Therapy in Head and Neck Squamous Cell Carcinoma Correlating the Expression Level of p38α
Volume: 10 Issue: 3
Author(s): Kamaldeep Gill, Rahul Kumar, Abhishek Gupta, Bidhu Kalyan Mohanti and Sharmistha Dey
Affiliation:
Keywords: p38α, HNSCC, radiation therapy, chemotherapy, surgery.
Abstract: p38α MAPK, a key therapeutic target in HNSCC can be considered as a prognostic marker and is implicated in response to radiation-therapy (RT). We compared the outcome of treatment viz. RT (group-I) and concurrent-RT (combination of RT with chemotherapy or surgery, group-II) with respect to p38α MAPK in HNSCC. The case-controlled study was performed on 143 HNSCC patients. From these p38α estimation was done thrice only for 104 patients (52 each in group-I and II), at pre, during and post-therapy periods using surface Plasmon resonance (SPR) technology, ELISA and western blot analysis. In HNSCC the over-expressed p38α levels declined after treatments in both the groups. The patients receiving only RT had a lower p38α level than those treated with concurrent-RT (p=0.009). Hence, p38α was found to be responsive to RT in HNSCC and it may be useful in predicting the treatment outcome and further improve the prognosis of disease in addition to clinical parameters.
Export Options
About this article
Cite this article as:
Gill Kamaldeep, Kumar Rahul, Gupta Abhishek, Mohanti Kalyan Bidhu and Dey Sharmistha, Comparative Analysis of Current Modality of Therapy in Head and Neck Squamous Cell Carcinoma Correlating the Expression Level of p38α, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/1573394710666141128001358
DOI https://dx.doi.org/10.2174/1573394710666141128001358 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
L-Sulforaphane Confers Protection Against Oxidative Stress in an In Vitro Model of Age-Related Macular Degeneration
Current Molecular Pharmacology How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Current Proteomics ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Genetic Mechanisms and Aberrant Gene Expression during the Development of Gastric Intestinal Metaplasia and Adenocarcinoma
Current Genomics What is the Current Role of Immunotherapy for Colon Cancer?
Reviews on Recent Clinical Trials Microbubble-Assisted p53, RB, and p130 Gene Transfer in Combination with Radiation Therapy in Prostate Cancer
Current Gene Therapy Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer
Anti-Cancer Agents in Medicinal Chemistry Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
Current Medicinal Chemistry Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Current Protein & Peptide Science Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Epidermolysis Bullosa: The Pediatricians Role
Current Pediatric Reviews Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Hypericin - A New Antiviral and Antitumor Photosensitizer: Mechanism of Action and Interaction with Biological Macromolecules
Current Drug Targets Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC
Current Pharmaceutical Design Realizing the Potential of Blueberry as Natural Inhibitor of Metastasis and Powerful Apoptosis Inducer: Tapping the Treasure Trove for Effective Regulation of Cell Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry